Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U01 Substudy 01F: MK-1084-based umbrella study in KRAS G12C-mutated nonsquamous NSCLC
2024-512248-47-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2 trial of calderasib in non-small cell lung cancer (NSCLC) (6 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experience a Dose Limiting Toxicity (DLT), Number of Participants Who Experience an Adverse Event (AE) and 2 more. Planned start Mar 2026; status: authorised.
02
Drugs
calderasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-512248-47-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512248-47-00.